Testing a diabetes drug to slow kidney disease progression
Treatments studied
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ADPKD (a genetic condition causing kidney cysts) and are between 18 and 60 years old.
- Your kidney function (eGFR) is at least 25 mL/min, and if you are 40–60, it must be below 90.
- Your kidney disease is growing quickly, as shown by a specific imaging class or genetic test.
- If you take blood pressure medicines (ACE inhibitors or ARBs), the dose must have been stable for at least 4 weeks.
- You have not used tolvaptan, a somatostatin drug, lithium, or an SGLT2 inhibitor in the last 3 months.
- You do not have type 1 diabetes, a history of diabetic ketoacidosis, or an active kidney infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This Phase 3 study tests whether taking metformin can slow the decline of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD). You may be eligible if you have ADPKD and signs that your kidneys are starting to decline faster than expected.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Hear when a new Polycystic Kidney, Autosomal Dominant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.